Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir +/- dasabuvir +/- ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience

AYGEN B., DEMİRTÜRK N., YILDIZ O., ÇELEN M. K., Celik I., Barut S., ...More

TURKISH JOURNAL OF GASTROENTEROLOGY, vol.31, no.4, pp.305-317, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 31 Issue: 4
  • Publication Date: 2020
  • Doi Number: 10.5152/tjg.2020.19197
  • Journal Name: TURKISH JOURNAL OF GASTROENTEROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.305-317
  • Keywords: Chronic hepatitis C, HCV genotypes 1 and 4, ombitasvir, paritaprevir, dasabuvir, real-world effectiveness, SUSTAINED VIROLOGICAL RESPONSE, RITONAVIR PLUS RIBAVIRIN, ANTIVIRAL THERAPY, HCV, OMBITASVIR, PARITAPREVIR, ABT-450/R-OMBITASVIR, MULTICENTER, PARITAPREVIR/RITONAVIR/OMBITASVIR, RETREATMENT
  • Erciyes University Affiliated: Yes

Abstract

Background/Aims: mbitasvir/paritaprevir/ritonavir (OMV/PTV/r) +/- dasabuvir (DSV) +/- ribavirin (RBV) combination has demonstrated excellent rates of sustained virologic response (SVR) and a very good safety profile in patients with the chronic hepatitis C virus (HCV) genotype 1 or 4 infections. We aimed to investigate the effectiveness and safety of OMV/PTV/r +/- DSV +/- RBV combination regimen in a real-world clinical practice.